NC318

NC318 is a first-in-class immunotherapeutic against a novel immunomodulatory target found on a restricted set of myeloid and tumor cells and on certain tumor types including lung, ovarian and head and neck cancers. Preclinical research shows that this target promotes suppressive myeloid cells and negatively regulates T cell function. NC318 targets the immunomodulatory pathway to prevent the formation and survival of suppressive myeloid cells, subsequently promoting T cell function and anti-tumor immunity. NC318 has the potential to treat multiple cancer indications owing to its unique ability to modulate immune responses in the tumor microenvironment of multiple cancer types. Preclinical research shows that S15 promotes the survival and differentiation of suppressive myeloid cells and negatively regulates T cell function, allowing cancer growth. In preclinical studies, NC318 blocks the negative effects of S15. NC318 is a first-in-class immunomedicine that has the potential to treat multiple cancer types. NextCure is moving NC318 forward initially for the treatment of solid cancers with the plan of filing an IND in late 2018.

NC410 is a novel immunotherapeutic designed to block an immune regulator expressed on T cells and suppressive antigen-presenting cell populations, including dendritic cell subpopulations. Scientific evidence shows that NC410 modulates T cell proliferation and differentiation of immune cell subpopulations, and plays a key role in mediating immune regulation. NextCure's translational work demonstrates that NC410 blocks the interaction of the target with its ligand, preventing inhibitory signaling in T cells and antigen-presenting cells, resulting in immune activation both in vitro and in animal tumor models. NC410 is potentially a unique product candidate that can treat both solid and blood-related tumor indications.

Functional, Integrated, NextCure Discovery in Immuno Oncology (FIND-IOTM) Technology
NextCure is addressing the major challenges in supplying next generation, novel targets to address limited treatment options for patients that do not respond to standard treatments or existing immune therapies. NextCure is utilizing FIND-IOTM technology to "functionally" identify targets that can impact immune responses. FIND-IOTM technology is focused on identifying novel cell surface molecular interactions that drive functional immune responses in the tumor microenvironment and other disease sites. We have developed proprietary approaches to functionally assess immune pathways in primary immune cells from healthy donors and patients with various diseases and established cell lines from immune and non-immune cell lineages including T cell subsets, monocytes, macrophage subpopulations and cancer cell lines.



With our current focus in immuno oncology, we have identified several positive and negative immune regulators of myeloid cells and T cells. From these discoveries, we are developing therapeutics that can intervene to modulate interactions of immune cells within the tumor microenvironment to restore anti-tumor activity.
NextCure is leveraging and applying its current FIND-IOTM technology to functional screening approaches for the identification of novel targets from multiple therapeutic areas, including autoimmunity and neurology, enabling next generation immunotherapeutics to fields beyond oncology with significant unmet medical needs to sustain the growth of the company.